ETV6‐NTRK3 fusion was detected in 1.6% (2/122) of SCLC, which was relatively rare, but may suggest a response to pan‐NTRK as well as ALK and ROS1 tyrosine kinase inhibitors. The gene discussed is ALK; the disease is small cell lung carcinoma.